Contribution of biomarkers to personalized medicine by Hayes, Daniel F
Th   e theme of the 2009 Annual Meeting of the American 
Society of Clinical Oncology (ASCO), presided by Dr 
Richard L Schilsky, was ‘Personalizing Cancer Care’ [1]. 
Dr Schilsky noted that ‘as oncologists, our focus has 
always been, and must remain, treating the patient, not 
the disease. We must each acquire the skills and make the 
commitment to do so in an optimal way.’
In an era of increasingly common therapies that are 
directed towards a speciﬁ  c target, Dr. Schilsky’s words 
ring true, but also raise the question, ‘what skills and 
what commitment?’ Personalized cancer care requires a 
thorough knowledge and understanding of evidence-
based medicine, particularly as it applies to the judicious 
use of biomarkers to carefully select patients most likely 
to beneﬁ  t and least likely to suﬀ  er toxicities from our 
therapies. Indeed, the remarkable reduction in mortality 
from breast cancer over the past four decades raises a 
second question that, indeed, challenges the concept of 
personalized care: ‘Should we treat all patients with every 
new therapy in order to maximize this reduction?’ Unless 
a patient is willing to accept any toxicity for the smallest 
gain, and society is willing to pay for it, the obvious 
answer is ‘no’. Sadly, with only a few exceptions, the ﬁ  eld 
has fallen far short of providing the sort of data that are 
required to reliably identify those patients who are so 
unlikely to beneﬁ  t that they would forego therapy. In fact, 
the ASCO Tumor Marker Guidelines Committee has 
recommended only ﬁ  ve markers that might be used to 
make clinical decisions regarding patients with newly 
diagnosed breast cancer: estrogen receptor (ER) and 
progesterone receptor (to select patients for endocrine 
therapy), human epidermal growth factor receptor 2 
(HER2; to select patients for anti-HER2 therapies, in 
particular trastuzumab and labatinib), and urokinase-
type plasmino  gen activator (uPA)/plasminogen activator 
inhibitor-1 (PAI1) and/or the 21 gene Recurrence Score 
to identify patients with node negative, ER-positive 
breast cancer whose prognosis is so good that 
chemotherapy is very unlikely to be of beneﬁ  t [2].
Why are these recommendations so conservative? Th  e 
ASCO Tumor Marker Guidelines Committee and others 
have generated proposals to provide a framework in 
which the relative value of a tumor marker might be 
evaluated objectively. In this regard, it is important to 
determine the intended use of the marker, such as 
determining prognosis or predicting that a generic class 
of treatments (for example, endocrine or chemotherapy) 
or speciﬁ  c agents (for example, anti-NERC therapies) will 
work against the particular tumor. Secondly, it is essential 
that the clinician be able to estimate the relative 
magnitude in the diﬀ  erence of outcomes for patients who 
are ‘positive’ versus those who are ‘negative’ for the 
marker, and whether that magnitude is suﬃ   cient to guide 
treatment diﬀ  erently than if the data were not available 
[3]. Importantly, it is critical that this estimate be accurate 
and reliable. Th   e Guidelines Committee jointly published 
a framework, designated the Tumor Marker Utility 
Grading System, in which they ﬁ  rst proposed a hierarchy 
of levels of evidence that might be used to determine if 
available data support the use of a marker of not [4]. Th  is 
level of evidence scale has recently been revised to 
distinguish data generated from prospective clinical trials 
in which the marker is the primary objective of the study 
[5,6] from those in which archived specimens are used 
[7]. Many of these concepts have recently been codiﬁ  ed 
by the Evaluation of Genomic Applications in Practice 
and Prevention (EGAPP) Initiative [8], in which tumor 
marker evaluation was placed into three semantic states: 
analytical validity - the importance of a stable, accurate, 
and reproducible assay for the marker; clinical validity - 
evidence that the marker does, indeed, separate two 
subgroups of patients with diﬀ  erent outcomes within a 
large population; and clinical utility - evidence that use of 
the marker improves outcomes compared to not using it.
It is absolutely essential that, before a marker be 
ordered or used to make clinical decisions, analytical 
validity is established. Doing so takes enormous eﬀ  ort 
and conscientious care to ‘get it right’. Recently, ASCO 
and the College of American Pathologists (CAP) have 
partnered to convene two expert panels to review not  © 2010 BioMed Central Ltd
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performing HER2 [9] and ER [10] assays, the two most 
critical biomarkers in breast cancer, if not all of oncology. 
Incredibly, these panels found large variation in the 
standardization and quality of the assays for these two 
markers, and they established proﬁ  ciency  testing. 
Clinicians and patients are strongly urged to be certain 
that these markers are evaluated in an accredited 
laboratory that participates in the CAP, or similar, 
proﬁ  ciency testing program.
Assuming analytical validity is established, why do we 
not have more markers with high levels of evidence to 
support clinical utility? A cursory review reveals more 
than 1,000 papers published during the past decade in 
the English literature regarding breast cancer and tumor 
markers, biomarkers, or prognostic or predictive factors. 
However, most, if not all of these provide only clinical 
validity, with little or no eﬀ   ort to produce high level 
evidence for clinical utility, principally because to do so 
requires careful planning, hard work, extensive time, and 
substantial cost. In general, there is a very poor valuation 
for tumor marker use, research, funding, reimbursement, 
or evaluation by our society and profession. Th  ese  issues 
have established a ‘vicious cycle’ in which marker 
research is under-funded and lacks the rigor of basic 
laboratory or therapeutic clinical research, and therefore 
marker use is based on low level data.
Clinicians must recognize that a bad tumor marker is 
every bit as harmful as a bad drug. It will take 
fundamental changes in all aspects of marker research 
and clinical use to break this cycle. In fact, several 
initiatives have begun to do so. In addition to the deﬁ  ni-
tions and levels of evidence scales discussed above, 
McShane and colleagues [11] published reporting recom-
men  dations for tumor marker prognostic studies 
(REMARK criteria), which have been endorsed, although 
not as widely adopted as hoped, by many journal editors. 
Furthermore, the National Cancer Institute of the United 
States established a new, separate study section (the 
Cancer Biomarkers Study Section) speciﬁ  cally to provide 
high levels of expertise in peer review of grants focused 
on tumor marker research. Th   e National Cancer Institute 
has also established a unique Oﬃ   ce of Biorepository and 
BioSpecimen Research with the mission of ‘developing a 
biorepository infrastructure that promotes resource 
sharing and team science in order to facilitate multi-
institutional high throughput genomic and proteomic 
studies’.
One hopes that these and future initiatives will raise 
the level of tumor marker research to that of therapeutics, 
so that clinicians, and patients, can reliably apply the 
long-sought concepts of ‘personalized cancer care’.
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